Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopia, a Common and Progressive Eye Condition

/PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced new data, including the full results from the Phase 3 GEMINI 1 clinical study, evaluating the efficacy, safety and tolerability...

AGN : 193.02 (+0.02%)
ABBV : 118.19 (+0.55%)
Inflation in Canada, U.S. Durable Goods Due Next Week

Monday U.S. Economic Lookahead New Home Sales (June) Featured Earnings Tesla Inc. (NASDAQ:TSLA) ...

TSLA : 643.38 (-0.91%)
LMT : 380.77 (+0.22%)
CDNS : 145.67 (+1.85%)
OTIS : 88.52 (+1.36%)
AAPL : 148.56 (+1.20%)
MSFT : 289.67 (+1.23%)
GOOGL : 2,660.30 (+3.58%)
V : 249.02 (+2.00%)
FB : 369.79 (+5.30%)
PYPL : 308.53 (+1.59%)
PFE : 41.68 (+0.51%)
TMO : 532.26 (+1.48%)
AMZN : 3,656.64 (+0.51%)
MA : 393.26 (+2.90%)
CMCSA : 58.36 (+0.99%)
MRK : 77.54 (+1.32%)
PG : 139.79 (+1.44%)
XOM : 57.04 (-0.12%)
ABBV : 118.19 (+0.55%)
CVX : 98.86 (+0.04%)
CLS.TO : 9.23 (+0.98%)
CMMC.TO : 3.50 (+1.45%)
TFII.TO : 130.40 (+1.86%)
Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports fiscal fourth-quarter results.

IRWD : 13.02 (+0.23%)
ABBV : 118.19 (+0.55%)
EXAS : 117.95 (-0.07%)
TLRY : 13.59 (-2.09%)
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

AbbVie (ABBV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ABBV : 118.19 (+0.55%)
DALVANCE® (dalbavancin) Receives FDA Approval to Treat Acute Bacterial Skin and Skin Structure Infections in Pediatric Patients

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved DALVANCE® (dalbavancin) for the treatment of acute bacterial skin and skin structure infections...

ABBV : 118.19 (+0.55%)
Why AbbVie (ABBV) Could Beat Earnings Estimates Again

AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

ABBV : 118.19 (+0.55%)
Pharma Stock Roundup: JNJ, NVS Q2 Earnings, PFE, ABBV, LLY & MRK FDA Updates

J&J (JNJ) and Novartis (NVS) announce Q2 results. FDA delays decisions on JAK inhibitor drugs of Lilly (LLY), AbbVie (ABBV) and Pfizer (PFE) for eczema indication.

GSK : 39.51 (+0.71%)
NVS : 91.57 (+0.54%)
RHHBY : 47.0300 (+1.31%)
JNJ : 171.79 (+1.06%)
PFE : 41.68 (+0.51%)
LLY : 244.15 (+2.37%)
ABBV : 118.19 (+0.55%)
Healthcare ETFs in Focus as Q2 Earnings Unfold

The healthcare sector has been benefiting from COVID-19 vaccines or treatment with many more to come.

BMY : 68.34 (+0.56%)
UNH : 417.70 (+0.46%)
JNJ : 171.79 (+1.06%)
PFE : 41.68 (+0.51%)
MRK : 77.54 (+1.32%)
AMGN : 247.72 (+1.22%)
GILD : 69.02 (+0.54%)
TMO : 532.26 (+1.48%)
ABBV : 118.19 (+0.55%)
XLV : 131.48 (+1.15%)
IYH : 284.43 (+1.06%)
VHT : 255.45 (+0.98%)
FHLC : 65.91 (+1.00%)
Roche's (RHHBY) 1H21 Sales Rise Despite Impact of Biosimilars

Roche's (RHHBY) performance in first-half 2021 was impressive on strong demand for new medicines and COVID-19 test kits. Impact of biosimilars continues to hurt sales.

REGN : 586.35 (-0.09%)
NVS : 91.57 (+0.54%)
RHHBY : 47.0300 (+1.31%)
ABBV : 118.19 (+0.55%)
Pfizer (PFE) Inks Vaccine Deal, Faces FDA Delay on JAK Drugs

Pfizer (PFE) partners with Biovac for manufacturing and distributing its COVID-19 vaccine in African Union. The FDA delays decision on Pfizer's regulatory filings for JAK inhibitors.

PFE : 41.68 (+0.51%)
LLY : 244.15 (+2.37%)
ABBV : 118.19 (+0.55%)
BNTX : 281.96 (+0.35%)
Respiratory Syntactical Virus (RSV) Market Size, Share, Trends, Analysis and Forecast 2027

The report on Respiratory Syntactical Virus (RSV) provides the clients with a comprehensive analysis of crucial driving factors, consumer behavior, growth trends, product utilization, key player analysis,...

ABT : 120.80 (+2.16%)
ABBV : 118.19 (+0.55%)
AZN : 58.23 (+0.47%)
GILD : 69.02 (+0.54%)
GSK : 39.51 (+0.71%)
HOLX : 72.30 (+0.74%)
LMNX : 36.99 (+0.03%)
MVRBF : 1.0400 (+4.00%)
MRK : 77.54 (+1.32%)
VRX.TO : 30.80 (-3.33%)
Why AbbVie (ABBV) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

ABBV : 118.19 (+0.55%)
Here's Why AbbVie (ABBV) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

ABBV : 118.19 (+0.55%)
AbbVie is on the Verge of a Breakout

AbbVie (ABBV) is nearing a key resistance level. If that level is surpassed, a breakout is expected. AbbVie, Inc. ( ABBV ) is a research-based biopharmaceutical company, which engages in the development...

ABBV : 118.19 (+0.55%)
AbbVie (ABBV) Venclexta Gets Breakthrough Therapy Tag for MDS

The FDA grants a Breakthrough Therapy designation to AbbVie's (ABBV) Venclexta in combination with azacitidine for treating adult patients with higher risk myelodysplastic syndrome.

RHHBY : 47.0300 (+1.31%)
JNJ : 171.79 (+1.06%)
ALXN : 182.50 (+1.70%)
ABBV : 118.19 (+0.55%)
Ardelyx (ARDX) Tumbles Following Deficiencies in Tenapanor NDA

The FDA notes deficiencies in the NDA seeking approval for Ardelyx's (ARDX) lead pipeline candidate, tenapanor, as a potential treatment for hyperphosphatemia.

IRWD : 13.02 (+0.23%)
ABBV : 118.19 (+0.55%)
ARDX : 1.68 (-5.08%)
BHC : 28.60 (+0.03%)
J&J (JNJ) Beats on Q2 Earnings & Sales, Ups View, Stock Rises

J&J (JNJ) beats second-quarter 2021 estimates for both earnings and sales. It raises its financial expectations for the year. It forecasts $2.5 billion in 2021 sales of COVID-19 vaccine.

JNJ : 171.79 (+1.06%)
PFE : 41.68 (+0.51%)
MRK : 77.54 (+1.32%)
ABBV : 118.19 (+0.55%)
Venetoclax (VENCLEXTA®) Granted US FDA Breakthrough Therapy Designation (BTD) in Higher Risk Myelodysplastic Syndrome (MDS)

/PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Therapy Designation (BTD) to venetoclax (VENCLEXTA) in combination with azacitidine...

ABBV : 118.19 (+0.55%)
Allergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the 2021 ASCRS (American Society of Cataract and Refractive Surgery) Annual Meeting

/PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced that it will present new data from its leading portfolio of eye care medicines at the 2021 ASCRS (American Society for Cataract...

AGN : 193.02 (+0.02%)
ABBV : 118.19 (+0.55%)
AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know

In the latest trading session, AbbVie (ABBV) closed at $115.42, marking a -1.77% move from the previous day.

ABBV : 118.19 (+0.55%)

Barchart Exclusives

Is Lumber Sending Another Signal?
The tidal wave of central bank liquidity and tsunami of government stimulus that flooded markets for more than a year has stoked inflationary fears. On July 19, a sudden correction in markets across most asset classes caused the inflation concerns to pivot towards stagflation fears. I watch lumber for clues, and the price of wood may be telling us that inflation remains the primary area of focus in late July 2021. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar